Clinical trials: mCRC
Triple Negative Breast Cancer, Endometrial Cancer
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
This is an open-label, multi-center, non-randomized, Phase 1b/2 study to assess the safety and efficacy of fruquintinib in combination with tislelizumab in patients with locally advanced or metastatic solid tumors.
- Conditions
- Triple Negative Breast Cancer, Endometrial Cancer, Solid Tumor, Unspecified, Adult, Colorectal Cancer
- Trial name
- NCT04577963
- Testing
- Fruquintinib, Tislelizumab
- Where
- 16 sites in United States
- Volunteers
- 52 people
- Sponsor
- Hutchmed
Liver Neoplasms, Colonic Neoplasms
Safety, Efficacy, and Dosing of Stereotactic Radiosurgery for Hepato-cellular Carc/Colo-rectal Liver Metastases
The purpose of this study is to determine a tolerable dose of radiation delivered by the CyberKnife system in two groups of patients with hepatocellular carcinoma (HCC).
- Conditions
- Liver Neoplasms, Colonic Neoplasms, Metastatic Cancer to Liver
- Trial name
- NCT01528878
- Testing
- Stereotactic Radiosurgery using the CyberKnife System.
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center